EP Patent

EP4563143A1 — A bilayer tablet formulation of metformin and sitagliptin comprising antioxidant

Assigned to Sanovel Ilac Sanayi ve Ticaret AS · Expires 2025-06-04 · 1y expired

What this patent protects

The present invention relates to a bilayer tablet comprising extended-release formulation having metformin or a pharmaceutically acceptable salt thereof and at least one cellulose derivates as binder and immediate release formulation having sitagliptin or a pharmaceutically accep…

USPTO Abstract

The present invention relates to a bilayer tablet comprising extended-release formulation having metformin or a pharmaceutically acceptable salt thereof and at least one cellulose derivates as binder and immediate release formulation having sitagliptin or a pharmaceutically acceptable salt thereof and at least one antioxidant. The present invention also relates to a simple, rapid, cost effective, time-saving and industrially convenient process of preparing the bilayer tablet.

Drugs covered by this patent

Patent Metadata

Patent number
EP4563143A1
Jurisdiction
EP
Classification
—
Expires
2025-06-04
Drug substance claim
No
Drug product claim
No
Assignee
Sanovel Ilac Sanayi ve Ticaret AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.